DUBLIN--(BUSINESS WIRE)--The "Immunoglobulin A Nephropathy Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the period 2016-2025.
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration.
The drugs candidates that are being developed by the different pharmaceutical companies have demonstrated positive clinical trial results which in-turn increase their further development. For instance, in May 2017 OMS721, a drug candidate developed by the Omeros Corporation demonstrated positive clinical trial results in the treatment of patients with IgA nephropathy. In December 2016, Anthera Pharmaceuticals, Inc. presented positive clinical trial results of blisibimod in 48-week, Phase II study in the treatment of patients with IgA nephropathy.
Companies are developing drugs with promising targets for the treatment of the disease. The potential targets may possibly stop or slow the progression of the disease with better efficacy and less side effects. Potential targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS), melanocortin receptors, and NF-κB signaling can also prove to be effective in IgA nephropathy treatment, since clinical trials of drug candidates meant to act on these targets have shown promising results. This is encouraging companies to further invest in their pipeline to develop drugs acting on new targets, thereby, fueling the growth of the pipeline.
Various new technologies are being used by the companies for the development of drugs to treat IgA nephropathy. For instance, TARGIT drug delivery technology is being used by Calliditas Therapeutics AB for the development of novel drug therapies.
Some of the key players developing drugs for the treatment of IgA nephropathy include Mallinckrodt plc, Merck KGaA, Novartis AG, and Shire plc.
Key Topics Covered
1. Research Background
2. Research Methodology
3. Executive Summary
4. Pipeline Outlook
5. IgA Nephropathy Epidemiology Overview
6. Immunoglobulin a (IgA) Nephropathy Therapeutics Pipeline Analysis by Phase (2018)
7. Clinical Trials Review
8. Competitive Landscape
9. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/5cgjct/immunoglobulin_a?w=4